Pediatric Cancer Biomarkers Market By Biomarker Type (Genetic and Genomic Biomarkers, MRD Biomarkers, Epigenetic and Methylation Biomarkers, Proteomic and Immunophenotypic Biomarkers, Liquid Biopsy Biomarkers, Others); By Cancer Type (Leukemia, Brain and CNS Tumors, Neuroblastoma, Sarcomas, Lymphomas, Wilms Tumor, Other Pediatric Cancers); By Testing Application (Diagnosis and Molecular Classification, Risk Stratification, Treatment Selection, MRD and Treatment Monitoring, Relapse and Recurrence Assessment); By Technology Platform (Next-Generation Sequencing, Flow Cytometry, PCR and qPCR, FISH and Cytogenetics, Immunohistochemistry, Methylation Profiling, Liquid Biopsy Platforms, Others); By End User (Hospitals and Pediatric Cancer Centers, Reference and Diagnostic Laboratories, Academic and Research Institutions, Biopharmaceutical Companies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Pediatric Cancer Biomarkers Market: Serial MRD Testing, Molecular Classification, and Target-Linked Assays Reshape Childhood Oncology

The Global Pediatric Cancer Biomarkers Market was valued at USD 824.7 million in 2025 and is projected to reach USD 1.39 billion by 2032, growing at a CAGR of 9.13%, according to Strategic Market Research.

 

The pediatric cancer biomarkers market includes laboratory testing used to classify tumor subtypes, define molecular risk, guide biomarker-directed treatment, and monitor measurable residual or recurrent disease. Revenue is generated through flow cytometry, cytogenetics, FISH, PCR, immunohistochemistry, DNA/RNA sequencing, methylation profiling, germline testing, measurable residual disease assays, biochemical monitoring, and emerging liquid biopsy platforms.

 

Reliable market aggregation is limited by hospital-bundled pathology, laboratory-developed tests, research-funded profiling, overlapping methodologies, and repeated monitoring. Completed biomarker-linked reports or test events better reflect demand than biomarker counts, as one child may require several diagnostic reports and multiple MRD assessments during therapy.

 

Patient Numbers Understate Laboratory Demand

Approximately 14,910 children and adolescents aged 0–19 were expected to be diagnosed with cancer in the United States in 2024, while 1,590 were expected to die from the disease. Globally, around 400,000 people in the same age group develop cancer annually. IARC recorded more than 275,000 diagnosed cases and over 105,000 deaths in 2022, although incomplete diagnosis and cancer registration reduce observed totals.

Incident cases represent only the starting point for test demand. A child with leukemia may require immunophenotyping, karyotyping, fusion analysis, targeted sequencing, and several MRD assessments. Central nervous system tumors increasingly require histopathology, mutation and fusion testing, and methylation classification. Relapsed solid tumors may generate repeat biopsies and broader profiling when standard treatment options have been exhausted.

More than 90% of U.S. pediatric cancer patients receive care at Children’s Oncology Group-affiliated institutions. Laboratory purchasing, assay validation, and treatment-linked testing decisions are therefore concentrated among academic hospitals and specialist pediatric cancer centers rather than community practices.

 

Pediatric Tumor Biology Favors Fusion and Epigenetic Testing

Childhood cancers often carry lineage-defining gene fusions, chromosomal gains or losses, developmental-pathway alterations, copy-number changes, and epigenetic signatures rather than the extensive mutation patterns found in many adult solid tumors.

EWSR1-family fusions confirm Ewing sarcoma, FOXO1 fusions refine rhabdomyosarcoma risk, BCR::ABL1 and related rearrangements define leukemia subtypes, MYCN amplification affects neuroblastoma risk classification, and BRAF or H3 K27 alterations influence the management of pediatric brain tumors.

RNA sequencing, anchored fusion assays, FISH, RT-PCR, and methylation classifiers remain commercially important alongside DNA panels. DNA-only assays can miss clinically relevant RNA fusions, while adult-focused panels may identify variants without explaining their relevance to childhood treatment protocols. Pediatric oncology laboratories require low-input performance, fusion coverage, age-specific interpretation, and reports that connect results with risk groups, approved therapies, or clinical trials.

 

Leukemia MRD Anchors Recurring Test Revenue

Approximately 3,100 U.S. children and adolescents younger than 20 are diagnosed with acute lymphoblastic leukemia each year. Diagnostic testing establishes lineage and molecular subtype, while MRD testing measures malignant cells that remain after treatment. Nearly all major cooperative groups use end-of-induction MRD to determine subsequent treatment intensity.

Flow cytometry and PCR can routinely detect approximately one malignant cell among 10,000 cells. High-throughput sequencing can extend sensitivity toward one malignant cell among one million. In an analysis involving 619 children, sequencing identified approximately 30% more MRD-positive samples than flow cytometry at a 0.01% threshold. Standard-risk patients with undetectable disease by sequencing recorded five-year event-free survival of 98.1%.

MRD testing may be ordered after induction, during consolidation, before or after transplantation, and during relapse surveillance. Each patient can therefore generate several reportable test events, giving MRD a more predictable repeat-order profile than one-time tumor classification.

Adaptive Biotechnologies delivered 105,587 clonoSEQ tests across all ages and covered indications in 2025, representing 39% growth from 2024. Pediatric volumes were not disclosed separately, but the all-age result demonstrates the scale available to centralized MRD providers when clinical protocols, reimbursement, and electronic ordering support repeat testing.

 

Risk Markers Direct Treatment Intensity

More than 650 U.S. children are diagnosed with neuroblastoma annually. MYCN amplification occurs in approximately 16%–25% of cases and in roughly 40%–50% of high-risk disease. In one Children’s Oncology Group cohort, five-year overall survival reached 87% for MYCN-nonamplified tumors and 57% for amplified tumors.

Applying the reported prevalence range to annual U.S. incidence produces an estimated minimum of approximately 104–163 newly diagnosed MYCN-amplified patients per year:

 

CNS Molecular Results Now Control Drug Eligibility

Approximately 4,300 U.S. children are diagnosed with brain tumors each year, creating the largest pediatric solid-tumor testing population. Molecular findings increasingly supplement or replace morphology when tumors with similar microscopic appearances carry different prognoses or treatment options.

BRAF V600E occurred in 17% of a cohort containing more than 400 pediatric low-grade gliomas. Ten-year progression-free survival was 27% among patients with the alteration and 60% among those without it. BRAF V600E mutations and BRAF fusions require separate reporting because their biology and treatment response differ.

FDA granted accelerated approval to tovorafenib in April 2024 for patients aged six months and older with relapsed or refractory pediatric low-grade glioma carrying a BRAF fusion, rearrangement, or V600 mutation. The overall response rate reached 51% among 76 evaluable patients. BRAF testing now affects treatment access as well as tumor classification.

FDA approved dordaviprone in August 2025 for adults and children aged one year and older with progressive H3 K27M-mutant diffuse midline glioma. The approval established the first FDA-authorized systemic treatment for this molecularly defined disease and placed H3 K27M testing directly within the treatment pathway.

 

Fusion-Positive Tumors Increase Demand for RNA-Capable Panels

NTRK, RET, ALK, and other kinase fusions occur in small pediatric subgroups, but a positive result may provide an alternative to highly morbid surgery, support treatment after standard therapy fails, or qualify a child for a tumor-agnostic drug.

FDA approved repotrectinib in June 2024 for adults and children aged 12 years and older with qualifying NTRK fusion-positive solid tumors. In July 2026, FDA granted traditional approval to selpercatinib for adults and children aged two years and older with locally advanced or metastatic RET fusion-positive solid tumors meeting label requirements. The selpercatinib indication requires confirmation through an FDA-approved test.

Illumina’s FDA-approved TruSight Oncology Comprehensive assay evaluates 517 DNA genes and 25 RNA genes and includes companion-diagnostic claims for NTRK and RET fusions. RNA capability has particular value in pediatric oncology because mutation-only panels can miss the structural changes that define treatment eligibility.

 

Public Programs Expand Testing but Reduce Billable Volume

NCI’s Molecular Characterization Initiative has enrolled more than 9,000 participants. Eligible children and young adults with selected CNS tumors, soft-tissue sarcomas, high-risk neuroblastoma, rare tumors, and metastatic Ewing sarcoma receive molecular testing at no cost through participating Children’s Oncology Group institutions. Results are generally returned within approximately 21 days.

Sponsored testing increases access and standardizes data collection, but it cannot be counted as commercial laboratory revenue. Participating patients may also receive locally billed pathology, cytogenetics, and monitoring tests, creating overlap between publicly funded profiling and routine clinical services.

Pediatric MATCH illustrates the decline between molecular detection and treatment use. Among the first 1,000 relapsed or refractory tumors, 31.5% contained an actionable alteration, 28.4% received a treatment-arm assignment, and 13.1% enrolled in a matched arm. Profiling succeeded in more than 94% of submitted tumors.

Trial availability, eligibility criteria, geographic access, declining patient condition, and family decisions reduce conversion from an actionable result to matched treatment. Laboratories increasingly need to demonstrate treatment changes, trial referrals, or risk reclassification rather than reporting the number of potentially actionable alterations alone.

 

Liquid Biopsy Remains Concentrated in High-Risk Monitoring

Circulating tumor DNA may reduce dependence on repeated tissue biopsies and detect treatment response or recurrence before conventional imaging. Initial adoption is most likely in high-risk tumors with a known fusion, mutation, or clonotype that can be tracked over time.

In Ewing sarcoma research cohorts, detectable ctDNA at diagnosis was associated with three-year event-free survival of 48.6%, compared with 82.1% among patients without detectable ctDNA. Persistence after early chemotherapy was also associated with poorer outcomes.

Inconsistent collection protocols, small pediatric study populations, platform differences, uncertain thresholds, and limited payer coverage continue to restrict routine use. Tissue profiling, marrow testing, flow cytometry, FISH, PCR, and established MRD assays remain the principal commercial methods.

 

Global Revenue Depends on Diagnostic Infrastructure

WHO estimates that more than 80% of children with cancer are cured in high-income countries, compared with less than 30% in many low- and middle-income countries. Only 29% of low-income countries report that cancer medicines are generally available, compared with 96% of high-income countries. Diagnostic delays, incorrect classification, treatment abandonment, toxicity, and relapse contribute to the survival gap.

Lower-resource health systems are more likely to expand first through leukemia flow panels, FISH, PCR, immunohistochemistry, digital pathology, regional sample-referral networks, and centralized sequencing hubs. Comprehensive genomic and methylation profiling has limited clinical value where tissue handling is unreliable or biomarker-linked treatment cannot be accessed.

 

Genomic Assays Hold the Largest Revenue Share

Genetic and genomic biomarkers accounted for approximately 49% of 2025 revenue and will expand at a 12.8% CAGR through 2032. The segment includes mutation, fusion, copy-number, methylation, and germline testing. High assay prices and growing requirements for BRAF classification, CNS molecular diagnosis, and NTRK or RET treatment selection support its lead. Liquid-biopsy biomarkers represented less than 8% of revenue but are estimated to grow at approximately 17.2% annually from a smaller clinical base.

 

MRD Outpaces One-Time Diagnostic Testing

Diagnosis and molecular classification represented an estimated 39% of 2025 revenue and are projected to grow at a 10.7% CAGR through 2032. MRD and treatment monitoring accounted for approximately 28% and are forecast to grow at 14.3% annually. Diagnostic testing reaches nearly every confirmed patient, while MRD produces several tests during treatment. Greater sequencing sensitivity, post-transplant surveillance, and treatment changes based on residual disease support faster revenue growth in monitoring.

 

Leukemia Retains the Largest Disease Share

Leukemia biomarkers accounted for an estimated 43% of 2025 revenue and are projected to grow at a 12.1% CAGR through 2032. Diagnostic genetics, flow cytometry, fusion testing, and serial MRD support the segment’s lead. CNS tumors represented approximately 23% and are forecast to expand at 14.0% annually as methylation profiling, RNA fusion analysis, BRAF-directed therapy, and H3 K27M-linked treatment become more widely incorporated into care.

 

Reference Laboratories Gain High-Complexity Work

Hospitals and academic pediatric cancer centers generated an estimated 62% of 2025 revenue and are expected to grow at a 10.9% CAGR through 2032. Central reference laboratories held approximately 27% and are projected to expand at 14.1% annually. Specialist centers control biopsy, pathology, and treatment decisions, while reference laboratories attract low-volume fusion assays, methylation classifiers, broad sequencing, and high-sensitivity MRD tests that are costly to validate locally.

 

North America Leads While Asia-Pacific Expands Capacity

North America accounted for an estimated 45% of 2025 revenue and is projected to grow at an 11.8% CAGR through 2032. Children’s Oncology Group concentration, centralized MRD adoption, FDA-linked molecular testing, payer infrastructure, and public profiling programs support regional leadership. Asia-Pacific is expected to record the fastest CAGR at approximately 14.2% as pediatric oncology centers, sequencing capacity, and referral laboratories expand. Country-level growth will depend on diagnosis rates, pathology quality, insurance coverage, and access to targeted medicines.

 

Assay Performance and Clinical Interpretation Shape Competition

Adaptive Biotechnologies holds a visible position in centralized sequencing-based MRD through clonoSEQ. Illumina supplies sequencing instruments and reagents and has expanded into regulated comprehensive profiling through TruSight Oncology Comprehensive. Academic hospitals and specialist laboratories retain substantial control over flow MRD, FISH, RNA fusion testing, methylation classification, and pediatric interpretation through internally validated assays.

NCI and the Children’s Oncology Group influence assay adoption through protocol design, Pediatric MATCH, and the Molecular Characterization Initiative. Their programs shape testing standards and access but do not compete as commercial diagnostic suppliers.

Drug developers increasingly determine which alterations enter routine testing. Day One Biopharmaceuticals has expanded demand for detailed BRAF testing through tovorafenib. Jazz Pharmaceuticals has linked H3 K27M status with dordaviprone eligibility. Eli Lilly’s selpercatinib approval supports FDA-approved RET fusion testing, while Bristol Myers Squibb and other tumor-agnostic therapy suppliers increase demand for RNA-capable NTRK assays.

Laboratories with reliable performance on small or degraded specimens, combined DNA and RNA analysis, pediatric-specific interpretation, and treatment-compatible turnaround have stronger positioning than vendors competing mainly on panel size. A report that identifies hundreds of variants has limited clinical value when it does not resolve tumor class, risk group, or drug eligibility.

 

Regulation Maintains a Mixed Testing Structure

The U.S. market includes FDA-authorized assays, FDA-approved companion diagnostics, and hospital or reference-laboratory LDTs. A federal district court vacated FDA’s 2024 LDT final rule on March 31, 2025. FDA restored the regulatory text that existed before the rule in September 2025.

CLIA oversight, internal laboratory validation, payer medical-necessity rules, drug labels, and FDA companion-diagnostic requirements now apply differently across individual assays.

Medicaid, the Children’s Health Insurance Program, and commercial insurers cover most pediatric patients, creating variation in reimbursement for broad tumor profiling, paired germline analysis, methylation classification, MRD, and investigational ctDNA. Tests linked to risk reassignment, therapy selection, or treatment monitoring have a stronger reimbursement case than assays supported only by analytical sensitivity.

 

Revenue Growth Will Come from More Testing per Patient

Pediatric cancer incidence is unlikely to change enough to determine market growth through 2032. Revenue will rise as more children receive integrated DNA and RNA testing, MRD sensitivity improves, tumors are retested at relapse, molecular classification replaces morphology-only diagnosis, and additional therapies require alteration-specific results.

Leukemia MRD will remain the most reliable source of repeat revenue. CNS tumors will generate faster growth in high-complexity sequencing and methylation profiling. Tumor-agnostic drug approvals will increase RNA fusion testing, while ctDNA adoption will remain concentrated in research, high-risk monitoring, and relapse assessment until prospective clinical utility and reimbursement become more consistent.

 

Pediatric Cancer Biomarkers Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 824.7 Million
Revenue Forecast in 2032	USD 1.39 Billion
Overall Growth Rate	CAGR of 9.13% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Biomarker Type, By Cancer Type, By Testing Application, By Technology Platform, By End User, By Geography
By Biomarker Type	Genetic and Genomic Biomarkers, MRD Biomarkers, Epigenetic and Methylation Biomarkers, Proteomic and Immunophenotypic Biomarkers, Liquid Biopsy Biomarkers, Others
By Cancer Type	Leukemia, Brain and CNS Tumors, Neuroblastoma, Sarcomas, Lymphomas, Wilms Tumor, Other Pediatric Cancers
By Testing Application	Diagnosis and Molecular Classification, Risk Stratification, Treatment Selection, MRD and Treatment Monitoring, Relapse and Recurrence Assessment
By Technology Platform	Next-Generation Sequencing, Flow Cytometry, PCR and qPCR, FISH and Cytogenetics, Immunohistochemistry, Methylation Profiling, Liquid Biopsy Platforms, Others
By End User	Hospitals and Pediatric Cancer Centers, Reference and Diagnostic Laboratories, Academic and Research Institutions, Biopharmaceutical Companies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Increasing use of serial MRD testing during leukemia treatment Wider adoption of molecular classification and pediatric-specific DNA/RNA assays Expansion of biomarker-linked therapies and companion diagnostics
Customization Option	Available upon request